Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

7.830 +0.470 (+6.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutic Com

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Faruqi & Faruqi Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE
From Faruqi & Faruqi LLP
Via GlobeNewswire
Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Shareholder Rights Attorneys Robbins LLP Reminds SAGE Stockholders of the Opportunity to Lead the Sage Therapeutics, Inc. Class Action
From Robbins LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE
From The Rosen Law Firm PA
Via GlobeNewswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SAGE Class Action Alert: Robbins LLP Reminds Stockholders of the Sage Therapeutics, Inc. Class Action
From Robbins LLP
Via GlobeNewswire
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
REMINDER – Sage Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the SAGE Class Action Lawsuit
From Robbins LLP
Via Business Wire
SAGE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Rosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) INVESTOR ALERT: Investors With Large Losses in Sage Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Sage Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.